Cytoki Presents Preclinical Data at ObesityWeek 2023

16 Oct 2023

Cytoki Pharma presents preclinical data demonstrating weight reduction and improved glucose control with lipidated IL-22 at ObesityWeek 2023.

Cytoki Pharma today presented preclinical data demonstrating the potential of lipidated IL-22 to induce weight loss and positively impact a range of cardiometabolic risk factors at ObesityWeek 2023, held October 14-17 in Dallas.

Read full press release

Cytoki Pharma raises 45M USD series A

5 May 2021

Cytoki closes $45M series A to harness IL-22 signaling for epithelial repair.

Cytoki Pharma today announced a $45 million series A financing led by existing investor Lundbeckfonden Emerge (Denmark) together with Seventure Partners (France), +ND Capital (Switzerland) and Ysios Capital (Spain). The series A will support the development of its lead program (lipidated IL-22) through clinical proof of concept in Inflammatory Bowel Disease and explore expansion in additional pathologies related to epithelial tissue injury.

Read full press release

Cytoki Pharma Highlighted in Medwatch

10 Dec 2019

Lundbeckfonden takes former Novo-boss’ biotech baby under its wing.

A new drug at Novo Nordisk’s lab sparked such big interest for Rasmus Jørgensen that he decided to leave the diabetes giant and build his own biotech firm from it. Now Lundbeckfonden will help him find the money.

Read article